---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-037511"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:10:56.708904+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vericel's NexoBrid gets FDA approval for pediatric severe burn treatment

## Summary
- FDA approved NexoBrid for eschar removal in pediatric patients with deep partial- and full-thickness thermal burns.
- Approval based on Phase 3 CIDS trial and additional pediatric data from earlier studies.
- Target customer base expands to approximately 20 pediatric burn centers in the U.S.
- NexoBrid was previously approved for adults in December 2022; pediatric indication adds new revenue opportunity.

## SEC filing metadata
- accession: 0001140361-24-037511
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000114036124037511/0001140361-24-037511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000114036124037511/ef20034225_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-037511
- JSON: https://secwatch.observer/filing/0001140361-24-037511.json
- Plain text: https://secwatch.observer/filing/0001140361-24-037511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.